Converge Bio secures $25M Series A for GenAI drug discovery lab

Generative AI drug discovery startup Converge Bio, with offices in Boston and Tel Aviv, has raised a $25 million Series A round led by Bessemer Venture Partners. The funding, reported on January 17, 2026, will scale its generative AI platform for antibody design, protein yield optimization, and biomarker discovery after an earlier $5.5 million seed round.